ORCA-1

Design

The ORCA-3 trial mirrors the Phase 3 ORCA-2 trial and is designed to obtain additional safety and efficacy data.

  • Placebo-controlled & double-blind
  • 3 treatment arms: Placebo vs 6 or 12 weeks cytisinicline
  • Cytisinicline treatment for 6 or 12 weeks

    • Does longer treatment lead to better efficacy?
    • Does continued treatment prevent early relapses?
  • Primary Endpoint: 4-week continuous abstinence ON treatment
  • Follow up to 6 months
ORCA-2 Schematic

ORCA-3 Trial Locations

ORCA-3 is being conducted at the following locations in the US.

AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY DC

Altoona Center for Clinical Research
https://www.altoonaarthritis.com/
800-924-7790 ext. 188

MediSphere Medical Research Center, LLC
https://www.medisphereresearch.com/
812-471-4110

Insight Research Institute
https://insightresearchinstitute.com/
810-213-8088

Alliance For Multispecialty Research
(AMR Fort Myers)
https://clinicalstudycenter.com/smoking-cessation-clinical-research-study/
239-908-0495

Jacksonville Center for Clinical Research
https://encoredocs.com/portfolio/smoking-cessation/
904-730-0101

Little Rock Allergy & Asthma Clinic
https://www.littlerockallergy.com/
1-800-514-4343